Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Non-Current Debt (2021 - 2025)

Coeptis Therapeutics Holdings has reported Non-Current Debt over the past 5 years, most recently at $150000.0 for Q4 2025.

  • Quarterly results put Non-Current Debt at $150000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $150000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $150000.0, changed 0.0%.
  • Non-Current Debt for Q4 2025 was $150000.0 at Coeptis Therapeutics Holdings, roughly flat from $150000.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for COEPW hit a ceiling of $1.6 million in Q4 2021 and a floor of $150000.0 in Q4 2022.
  • Median Non-Current Debt over the past 5 years was $150000.0 (2022), compared with a mean of $253333.4.
  • Biggest five-year swings in Non-Current Debt: tumbled 90.91% in 2022 and later changed 0.0% in 2023.
  • Coeptis Therapeutics Holdings' Non-Current Debt stood at $1.6 million in 2021, then tumbled by 90.91% to $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023, then changed by 0.0% to $150000.0 in 2024, then changed by 0.0% to $150000.0 in 2025.
  • The last three reported values for Non-Current Debt were $150000.0 (Q4 2025), $150000.0 (Q3 2025), and $150000.0 (Q2 2025) per Business Quant data.